---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-016285"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2025-06-24T23:59:59+00:00"
generated_at: "2026-05-18T22:58:33.946186+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MIRA reports preclinical data for SKNY-1: biased CB1 modulation, CB2 activity, selective MAO-B inhibition

## Summary
- SKNY-1 shows biased CB1 antagonism: blocks β-arrestin (cravings) but spares G-protein (mood stability), unlike rimonabant.
- Partial agonist at CB2 receptor, targeting metabolic regulation and inflammation for obesity comorbidities.
- Selective MAO-B inhibition; no MAO-A or D1/D2/D3 dopamine receptor activity, supporting CNS safety.
- Data from Eurofins in vitro studies; in vivo animal models for weight loss and nicotine addiction are being finalized.
- Acquisition of SKNY by MIRA remains subject to regulatory and shareholder approval.

## SEC filing metadata
- accession: 0001641172-25-016285
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2025-06-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000164117225016285/0001641172-25-016285-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000164117225016285/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-016285
- JSON: https://secwatch.observer/filing/0001641172-25-016285.json
- Plain text: https://secwatch.observer/filing/0001641172-25-016285.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.